Breaking News Instant updates and real-time market news.

IPCI

Intellipharmaceutics

$2.38

0.139 (6.20%)

, AZN

AstraZeneca

$32.29

0.03 (0.09%)

18:37
10/07/16
10/07
18:37
10/07/16
18:37

Intellipharmaceutics announces tentative FDA approval for generic Seroquel XR

Intellipharmaceutics (IPCI) announced that the Company received tentative approval from the U.S. FDA for the Company's abbreviated new drug application for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths. The Company's tentatively-approved product is a generic equivalent for the corresponding strengths of the branded product Seroquel XR sold in the United States by Astra Zeneca (AZN). Pursuant to a settlement agreement between the Company and AstraZeneca dated July 30, 2012, the Company is permitted to launch its generic versions of the 50, 150, 200, 300 and 400 mg strengths of generic Seroquel XR, on November 1, 2016, subject to FDA final approval of the Company's ANDA for those strengths. Such FDA final approval is subject to a 180 day exclusivity period relating to a prior filer or filers of a generic equivalent of the branded product. To our knowledge, two companies have first-to-file status and may be in a position to launch on November 1, 2016, although we cannot be certain of that date. Our intent is to launch these strengths after FDA final approval following expiry of the other companies' exclusivity period(s). There are currently no generics of Seroquel XR available in the U.S. market as the product is still under Astra Zeneca's patent protection until November 1, 2017. There can be no assurance that the Company's quetiapine fumarate extended-release tablets in any of the 50, 150, 200, 300 and 400 mg strengths will receive final FDA approval, or if approved, that they will be successfully commercialized.

IPCI

Intellipharmaceutics

$2.38

0.139 (6.20%)

AZN

AstraZeneca

$32.29

0.03 (0.09%)

  • 07

    Oct

  • 20

    Oct

  • 16

    Nov

IPCI Intellipharmaceutics
$2.38

0.139 (6.20%)

10/04/16
BMUR
10/04/16
INITIATION
Target $8
BMUR
Buy
Intellipharmaceutics assumed with a Buy at Brean Capital
Brean Capital analyst Difei Yang assumed coverage of Intellipharmaceutics with a Buy rating and $8 price target.
AZN AstraZeneca
$32.29

0.03 (0.09%)

09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.

TODAY'S FREE FLY STORIES

NUVA

NuVasive

$75.54

-1.15 (-1.50%)

08:08
06/28/17
06/28
08:08
06/28/17
08:08
Recommendations
NuVasive analyst commentary  »

NuVasive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 15

    Aug

CA

CA Technologies

$34.62

-0.19 (-0.55%)

08:08
06/28/17
06/28
08:08
06/28/17
08:08
Recommendations
CA Technologies analyst commentary  »

Potential CA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$60.84

-0.32 (-0.52%)

08:06
06/28/17
06/28
08:06
06/28/17
08:06
Initiation
XPO Logistics initiated  »

XPO Logistics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

MON

Monsanto

$117.25

-0.55 (-0.47%)

08:06
06/28/17
06/28
08:06
06/28/17
08:06
Earnings
Breaking Earnings news story on Monsanto »

Monsanto reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MON

Monsanto

$117.25

-0.55 (-0.47%)

08:05
06/28/17
06/28
08:05
06/28/17
08:05
Earnings
Monsanto reports Q3 EPS $1.90, consensus $1.76 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CBI

CB&I

$20.03

5.63 (39.10%)

08:04
06/28/17
06/28
08:04
06/28/17
08:04
Hot Stocks
CB&I awarded contract by Shurtan Gas Chemical Complex »

CB&I announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMNX

Luminex

$20.92

-0.3 (-1.41%)

08:04
06/28/17
06/28
08:04
06/28/17
08:04
Hot Stocks
Luminex receives CE-IVD mark for ARIES Norovirus Assay »

Luminex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NVIV

InVivo Therapeutics

$2.75

0.2 (7.84%)

08:04
06/28/17
06/28
08:04
06/28/17
08:04
Hot Stocks
InVivo Therapeutics reports two patients in study improve in INSPIRE assessments »

InVivo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MSA

MSA Safety

$79.73

0.44 (0.55%)

08:03
06/28/17
06/28
08:03
06/28/17
08:03
Hot Stocks
MSA Safety to acquire Globe Holding Company for $215M in cash »

MSA Safety announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Holdings

$86.01

-0.61 (-0.70%)

07:59
06/28/17
06/28
07:59
06/28/17
07:59
Initiation
HCA Holdings initiated  »

HCA Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$87.90

0.08 (0.09%)

07:59
06/28/17
06/28
07:59
06/28/17
07:59
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

OLN

Olin Corp.

$29.31

0.29 (1.00%)

07:58
06/28/17
06/28
07:58
06/28/17
07:58
Recommendations
Olin Corp. analyst commentary  »

Cowen calls Olin Corp. a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$10.40

0.09 (0.87%)

07:57
06/28/17
06/28
07:57
06/28/17
07:57
Recommendations
Daseke analyst commentary  »

Daseke revenue synergies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRU

TransUnion

$43.52

-0.78 (-1.76%)

07:57
06/28/17
06/28
07:57
06/28/17
07:57
Recommendations
TransUnion analyst commentary  »

TransUnion guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

COST

Costco

$159.26

-0.94 (-0.59%)

, AMZN

Amazon.com

$976.78

-17.2 (-1.73%)

07:56
06/28/17
06/28
07:56
06/28/17
07:56
Recommendations
Costco, Amazon.com analyst commentary  »

Costco weakness a buying…

COST

Costco

$159.26

-0.94 (-0.59%)

AMZN

Amazon.com

$976.78

-17.2 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Aug

PYPL

PayPal

$52.73

-1.01 (-1.88%)

07:55
06/28/17
06/28
07:55
06/28/17
07:55
Recommendations
PayPal analyst commentary  »

PayPal shares could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

07:55
06/28/17
06/28
07:55
06/28/17
07:55
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BSX

Boston Scientific

$27.81

0.09 (0.32%)

07:53
06/28/17
06/28
07:53
06/28/17
07:53
Recommendations
Boston Scientific analyst commentary  »

Boston Scientific Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ADMA

ADMA Biologics

$4.06

0.46 (12.78%)

07:50
06/28/17
06/28
07:50
06/28/17
07:50
Recommendations
ADMA Biologics analyst commentary  »

Biotest deal gives ADMA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

CKH

Seacor

$32.49

0.19 (0.59%)

07:49
06/28/17
06/28
07:49
06/28/17
07:49
Recommendations
Seacor analyst commentary  »

Seacor divestment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUSA

Murphy USA

$72.01

-0.44 (-0.61%)

07:48
06/28/17
06/28
07:48
06/28/17
07:48
Recommendations
Murphy USA analyst commentary  »

Murphy USA a top pick for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$6.14

-0.16 (-2.54%)

07:48
06/28/17
06/28
07:48
06/28/17
07:48
Hot Stocks
Ziopharm initiates stereotactic arm of Ad-RTS-hIL-12 + veledimex Phase 1 study »

Ziopharm announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVA

Sinovac Biotech

$6.34

-0.07 (-1.09%)

07:46
06/28/17
06/28
07:46
06/28/17
07:46
Hot Stocks
Sinobioway proposes $8 per share takeover of Sinovac Biotech »

The Shandong Sinobioway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$19.11

0.57 (3.07%)

07:46
06/28/17
06/28
07:46
06/28/17
07:46
Hot Stocks
Universal Stainless & Alloy reaches early labor agreement at Dunkirk facility »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$11.35

-0.12 (-1.05%)

07:45
06/28/17
06/28
07:45
06/28/17
07:45
Hot Stocks
Kratos Defense awarded UAV contract amendment by U.S. Navy »

Kratos Defense announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.